pramipexole


Also found in: Dictionary, Wikipedia.

pramipexole

 [pram″ĭ-pek´sōl]
a dopamine agonist used in the form of the dihydrochloride salt in treatment of parkinson's disease, administered orally.

pramipexole

(prăm′ə-pĕk′sōl′)
n.
A dopamine agonist used in the treatment of Parkinson's disease.

pramipexole

Mirapex® Neurology A dopamine antagonist used to manage Parkinson's disease Adverse effects Constipation, dry mouth, vision defects, insomnia
References in periodicals archive ?
If the insomnia is related to nocturnal motor symptoms, dopaminergic therapy (dopamine agonists [e.g., rotigotine transdermal patch], long-acting LDs [Sinemet], and monoamine oxidase B inhibitors) should be optimized initially (expert opinion) *Cognitive-behavioral therapy is the preferred option in PD patients with insomnia regardless of etiology (Level A recommendation by the American Academy of Sleep Medicine) *Dopamine agonists (e.g., rotigotine, pramipexole, and ropinirole), eszopiclone, and melatonin followed by rasagiline and doxepin may be considered for the management of insomnia in patients with PD (evidence based) *The pharmacological treatment of the insomnia in PD patients includes the treatment of insomnia itself and secondary insomnia in the context of PD progression.
After all, pramipexole was tapered off and gabapentin was switched to pregabalin.
Pramipexole and ropinirole can be used as monotherapy or as an adjunct to levodopa to treat bradykinesia, postural instability, and rigidity.
Ropinirole and pramipexole behave as high efficacy agonists at D2 and D3 dopamine receptors (D2R and D3R), displaying a preference for D3R [2, 12, 13].
Retinal safety of dopamine agonists required reinvestigation in humans because albino rat studies showed retinal degeneration with ropinirole, pramipexole, and rotigotine; this effect was not seen in albino mice or pigmented rats, monkeys, or pigs [9-11] but involved the pan-vertebrate process of disk shedding.
Pramipexole Dihydrochloride Tablets, the generic version of Mirapex, is available in 0.125-, 0.25-, 0.5-, 0.75-, 1- and 1.5-milligram 90-count bottles.
Pramipexole dihydrochloride tablets, the generic version of Mirapex, is available in 0.125, 0.25, 0.5, 0.75, 1 and 1.5 mg 90-count bottles and is used to treat the signs and symptoms of Parkinson's disease as well as treating restless legs syndrome (RLS).
Reddy's Laboratories (NYSE:RDY) revealed on Wednesday the availability of the US Food & Drug Administration (USFDA) approved PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in the US market on 11 August 2015.
Thirty patients (aged 20-80 years; mean age, 56 years) with restless legs syndrome and a low-normal serum ferritin level (15-50 ng/ml; suggestive of low or borderline-low iron status) were randomly assigned to receive ferrous sulfate (325 mg twice a day) or pramipexole (0.25 mg at bedtime, with the dosage adjusted at 2, 4, and 8 weeks according to response and tolerance) for 12 weeks.
Major finding: The proportional reporting ratio, similar to the relative risk ratio, was significant between pramipexole, ropinirole, cabergoline, bromocriptine, rotigotine, and apomorphine on one hand, and a variety of impulse control disorders on the other.
Multiple agents including dopamine agonists such as carbidopa/levadopa, ropinirole, and pramipexole as well as gabapentin, clonazepam, and opioids have been used in the management of RLS symptoms.
Oral iron supplementation and the dopamine-inhibiting drug pramipexole are equally effective for treating patients with restless legs syndrome and work along similar time frames, South Korean research shows.